Evaluation of dose-dependent effects of dapagliflozin on urinary glucose and plasma ketone bodies in healthy dogs | Synapse
March 3, 2026Open Access
Evaluation of dose-dependent effects of dapagliflozin on urinary glucose and plasma ketone bodies in healthy dogs
Key Points
Dapagliflozin reduces urinary glucose in a dose-dependent manner, indicating its efficacy for managing glucose levels.
Plasma ketone body levels also change with different doses of dapagliflozin, revealing insights into metabolic shifts.
Assessment of dapagliflozin's effects were conducted on healthy dogs, presenting a novel approach to diabetes management in canines.
Further studies are warranted to explore dapagliflozin's relevance in dogs suffering from heart failure and other health issues.
Abstract
This study provides preliminary insight into dapagliflozin's effects in healthy dogs; further studies are needed to assess relevance in dogs with heart failure.